Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2016 Jul 29;15(10):2302–2313. doi: 10.1158/1535-7163.MCT-15-0801

Figure 5.

Figure 5

Platinum compounds have additive effect with CNDAC. A, Chinese hamster wild-type line V79-4 (WT2) and BRCA2 deficient line V-C8 (−BRCA2) were exposed to CNDAC (CN, 2 – 20 nM) subsequent to addition of cisplatin (cis, 14 – 140 nM) or oxaliplatin (oxali, 24 –240 nM) and incubated for 24 hours before washout. The colonies formed were quantitated and clonogenicity of both lines were compared for treatment with cisplatin alone vs cisplatin-CNDAC combination at a fixed ratio (7:1, left) or oxaliplatin vs oxaliplatin-CNDAC combination at a fixed ratio (12:1, right). B, CHO cell lines deficient in RAD51D (−RAD51D) and complemented with RAD51D (+RAD51D) were treated concomitantly with cisplatin (12 – 240 nM) or oxaliplatin (50 – 1000 nM) and CNDAC (2 – 40 nM) in clonogenic assays as in A. Clonogenicity of both lines were compared for treatment with cisplatin alone vs cisplatin-CNDAC combination at a fixed ratio (6:1, left) or oxaliplatin vs oxaliplatin-CNDAC combination at a fixed ratio (25:1, right). C, CHO cell lines deficient in XRCC3 (−XRCC3) and complemented with XRCC3 (+XRCC3) were treated concomitantly with cisplatin (18 – 78 nM) or oxaliplatin (120 – 520 nM) and CNDAC (3 – 13 nM) for 24 hours before washout in clonogenic assays. Clonogenicity of both lines were compared for treatment with cisplatin alone vs cisplatin-CNDAC combination at a fixed ratio (6:1, left) or oxaliplatin vs oxaliplatin-CNDAC combination at a fixed ratio (40:1, right). In A - C, CIs of the respective deficient cell lines are presented in the accompanying inserts. D, wild type hamster lung cell line (WT2) was exposed to cisplatin (0.36 – 3.6 µM) or oxaliplatin (0.28 – 2.8 µM) followed by CNDAC (0.04 – 0.4 µM) as in A-C. Clonogenicity was compared for treatment with cisplatin alone vs cisplatin-CNDAC combination at a fixed ratio (9:1, left) or oxaliplatin vs oxaliplatin-CNDAC combination at a fixed ratio (7:1, right). E, wild type CHO cells (WT1) were exposed to cisplatin (0.9 – 4.5 µM) followed by CNDAC (0.2 – 1 µM) as in D. Clonogenicity was compared for treatment with cisplatin alone vs cisplatin-CNDAC combination at a fixed ratio (4.5:1). CIs of the wild-type lines in D - E are presented in the accompanying inserts.